LL-37 mastery course
Unit 9 of 12

Therapeutic development & delivery

LL-37 looks like an ideal drug on paper and behaves like a difficult one in practice. It is degraded by proteases, weak…

Why a promising peptide is so hard to turn into a drug

LL-37 looks like an ideal drug on paper and behaves like a difficult one in practice. It is degraded by proteases, weakened by salt and serum, can rupture human red blood cells (hemolysis), and is expensive to make. Turning it into a therapeutic means engineering around all of that.

This unit surveys the obstacles and the strategies: shorter and modified analogs, D-amino-acid and stabilized designs, nanoparticle and hydrogel delivery, fusion constructs, and where the whole pipeline actually stands. It is the practical bridge between LL-37 biology and any real-world use.

Key terms

The four big obstacles


Native peptide versus engineered analog


Ways to protect and place the peptide


Fusion constructs and the build process


Where the pipeline really stands